Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | GPR4 | P46093 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238050 | 0.97 | ACKR3 (0.37) | ACKR3EPHX2GPR119PDE3BPDE3A | |
| SCHEMBL2980444 | 0.92 | DRD3 (0.37) | PDE3BPDE3ADRD2DRD3 | |
| SCHEMBL2983864 | 0.90 | PDE3B (0.36) | PDE3BPDE3ADRD2DRD3 | |
| SCHEMBL2973307 | 0.89 | PDE3B (0.41) | PDE3BPDE3ADRD2DRD3 | |
| SCHEMBL2980471 | 0.89 | PDE3B (0.40) | PDE3BPDE3ADRD2DRD3 | |
| SCHEMBL2980391 | 0.89 | PDE3B (0.42) | PDE3BPDE3A | |
| SCHEMBL2975965 | 0.88 | CACNA2D1 (0.38) | PDE3BPDE3A | |
| SCHEMBL2983812 | 0.88 | PDE3B (0.36) | PDE3BPDE3ADRD2DRD3 | |
| SCHEMBL2983292 | 0.85 | GPR119 (0.38) | GPR119 | |
| SCHEMBL2975929 | 0.85 | PDE3B (0.34) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | ACKR3 3404/4885EPHX2 2549/4885GPR119 4211/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | ACKR3 3404/4885EPHX2 2549/4885GPR119 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.